ANI Pharmaceuticals Reiterates FY24 Outlook Of $520M-$542M Vs. $535.11M Estimate, Projects FY24 Adjusted EPS Of $4.26- $4.67 Vs. $4.48 Estimate

5/10/24 6:59:28 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ANIP alert in real time by email

ANI continues to expect total company adjusted non-GAAP gross margin between 62% and 63% and the Company will continue to tax effect non-GAAP adjustments for computation of adjusted non-GAAP diluted earnings per share at a tax rate of 26.0%.

The Company now anticipates between 19.4 million and 19.7 million shares outstanding (reflective of a full year of shares outstanding resulting from the May 2023 equity raise) for the purpose of calculating diluted EPS and now expects its U.S. GAAP effective tax rate to be between 22.0% to 25.0% as compared to 20.0% to 22.0%.

Get the next $ANIP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ANIP

Date	Price Target	Rating	Analyst
10/11/2024	$68.00	Overweight	Piper Sandler
3/15/2024	$80.00	Overweight	CapitalOne
8/22/2023	$60.00 → $73.00	Buy	H.C. Wainwright
3/1/2023	$55.00	Buy	Guggenheim
9/7/2022	$50.00	Buy	H.C. Wainwright
11/2/2021	$60.00 → $65.00	Outperform	Raymond James
11/2/2021	$70.00	Buy	Truist

More analyst ratings

$ANIP
Leadership Updates

Live Leadership Updates

ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors
-- Mr. Leonard is an accomplished leader with 35 years of pharmaceuticals and healthcare experience -- Mr. Leonard has significant expertise in pharmacy benefits management, health insurance, and specialty and retail pharmacy -- BAUDETTE, Minn., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the addition of Matthew J. Leonard, R.Ph. to its Board of Directors. Mr. Leonard brings more than 35 years of experience as an accomplished leader and innovator within the pharmaceutical industry. This appointment is effective immediately. "We are delighted to add Matthew (Matt) Leonard to our Board of Directors. With his deep leadershi
8/23/23 6:50:00 AM ET
$ANIP
Biotechnology: Pharmaceutical Preparations
Health Care
ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") today announced that Krista L. Davis will join the Company as Chief Human Resources Officer, effective September 12. Ms. Davis brings to the Company over 20 years of executive leadership experience in human resources, talent management, and organizational development. "Ms. Davis is an important addition to our leadership team and will bring strategic and innovative thought leadership to our priority people and organizational issues. Krista has a long track record of driving organizational effectiveness and delivering results across industries and cultures, most recently with Novartis, where she led global human resources for
9/12/22 6:50:00 AM ET
$ANIP
Biotechnology: Pharmaceutical Preparations
Health Care
ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Meredith W. Cook will join the Company as SVP, General Counsel and Corporate Secretary, effective July 18. Ms. Cook brings over 20 years of legal and leadership experience in specialty and generics pharmaceuticals, including in corporate governance, mergers and acquisitions (M&A), strategic transactions, and intellectual property (IP). "We are delighted to welcome Ms. Cook to our leadership team. Meredith is an accomplished attorney with demonstrated leadership and expertise in the pharmaceutical industry and will no doubt play an important role in the Company's continued growth. Her guidance and perspectives
7/18/22 6:50:00 AM ET
$ANIP
Biotechnology: Pharmaceutical Preparations
Health Care

$ANIP
Press Releases

Fastest customizable press release news feed in the world

ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance
Generated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.5%, and record Purified Cortrophin® Gel net revenues of $52.6 million, an increase of 76.8% year-over-yearNet loss of $(24.2) million and adjusted non-GAAP EBITDA of $35.1 millionDiluted GAAP loss per share of $(1.27) and adjusted non-GAAP diluted earnings per share of $1.34Completed the acquisition of Alimera Sciences, Inc. on September 16, 2024, adding two commercial assets ILUVIEN® and YUTIQ® with significant growth potential to its Rare Disease portfolioImplemented new capital structure that is expected to reduce interest expense by approximately $39.0 million on an annualized basis (1)Inc
11/8/24 6:50:28 AM ET
$ANIP
Biotechnology: Pharmaceutical Preparations
Health Care
ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November
PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at at two upcoming investor conferences as follows: • The Guggenheim Inaugural Healthcare Innovation Conference Wednesday, November 13, 2024, at 10:00am ET • The Jefferies London Healthcare Conference Wednesday, November 20, 2024, at 2:30pm GMT/9:30am ET The live and archived webcasts will be accessible from the Company's website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay
11/4/24 4:30:00 PM ET
$ANIP
Biotechnology: Pharmaceutical Preparations
Health Care
ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET
PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its third quarter 2024 financial results on Friday, November 8, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: DateFriday, November 8, 2024 Time8:00 a.m. ET Toll free (U.S.)800-445-7795 Conference ID4757982 Webcast (live and replay)www.anipharmaceuticals.com, under the "Investors" section A replay of the c
10/30/24 5:00:00 PM ET
$ANIP
Biotechnology: Pharmaceutical Preparations
Health Care

$ANIP
Market Insights

Live Market Insights

ANI's Generic L-Glutamine Oral Powder Hits Market, Targets $20.1M Annual Sales
ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched L-Glutamine Oral Powder. ANI's L-Glutamine Oral Powder is the generic version of the reference listed drug (RLD) Endari®. "The approval and launch of L-Glutamine Oral Powder, the first AA-rated approved generic to Endari®, continues to demonstrate the strong capabilities and execution of our R&D team. We remain focused on ensuring that patients in need, and the providers who care for them, have access to our high-quality therapeutics," stated Nikhil Lalwani, Presiden
7/15/24 7:05:00 AM ET
$ANIP
Biotechnology: Pharmaceutical Preparations
Health Care
ANI Pharmaceuticals Announces FDA Approval And Launch Of Its Naproxen Delayed-Release Tablets, USP
7/2/24 7:03:31 AM ET
$ANIP
Biotechnology: Pharmaceutical Preparations
Health Care
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Citigroup raised the price target for NVIDIA Corporation (NASDAQ:NVDA) from $126 to $150. Citigroup analyst Atif Malik maintained a Buy rating. NVIDIA shares gained 6.8% to close at $126.09 on Tuesday. See how other analysts view this stock. Truist Securities raised the price target for Rivian Automotive, Inc. (NASDAQ:RIVN) from $10 to $13. Truist Securities analyst Jordan Levy maintained a Hold rating. Rivian Automotive shares gained 8.6% to close at $11.96 on Tuesday. See how other analysts view
6/26/24 8:12:59 AM ET
$ACN
$AMZN
$ANIP
$EXAS
Business Services
Consumer Discretionary
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations

$ANIP
Financials

Live finance-specific insights

ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance
Generated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.5%, and record Purified Cortrophin® Gel net revenues of $52.6 million, an increase of 76.8% year-over-yearNet loss of $(24.2) million and adjusted non-GAAP EBITDA of $35.1 millionDiluted GAAP loss per share of $(1.27) and adjusted non-GAAP diluted earnings per share of $1.34Completed the acquisition of Alimera Sciences, Inc. on September 16, 2024, adding two commercial assets ILUVIEN® and YUTIQ® with significant growth potential to its Rare Disease portfolioImplemented new capital structure that is expected to reduce interest expense by approximately $39.0 million on an annualized basis (1)Inc
11/8/24 6:50:28 AM ET
$ANIP
Biotechnology: Pharmaceutical Preparations
Health Care
ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET
PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its third quarter 2024 financial results on Friday, November 8, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: DateFriday, November 8, 2024 Time8:00 a.m. ET Toll free (U.S.)800-445-7795 Conference ID4757982 Webcast (live and replay)www.anipharmaceuticals.com, under the "Investors" section A replay of the c
10/30/24 5:00:00 PM ET
$ANIP
Biotechnology: Pharmaceutical Preparations
Health Care
ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance
Generated record quarterly net revenues of $138.0 million, representing year-over-year growth of 18.4%, and record Rare Disease net revenues of $49.2 million, an increase of 102.4% year-over-yearDelivered adjusted non-GAAP EBITDA of $33.2 million, and adjusted non-GAAP diluted earnings per share of $1.02Net loss available to common shareholders of $(2.7) million and diluted GAAP loss per share of $(0.14)On track to close acquisition of Alimera Sciences, Inc. in the third quarter of 2024, adding two durable commercial assets ILUVIEN® and YUTIQ® with significant growth potential to its Rare Disease portfolioIncreased 2024 guidance with expected net revenues of $540 million to $560 million, adj
8/6/24 6:50:00 AM ET
$ANIP
Biotechnology: Pharmaceutical Preparations
Health Care

ANI Pharmaceuticals Reiterates FY24 Outlook Of $520M-$542M Vs. $535.11M Estimate, Projects FY24 Adjusted EPS Of $4.26- $4.67 Vs. $4.48 Estimate

Chat with this insight

Recent Analyst Ratings for $ANIP

$ANIP Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SVP, HEAD - ESTABLISHED BRANDS Rowland Thomas Andrew covered exercise/tax liability with 867 shares, decreasing direct ownership by 3% to 33,169 units (SEC Form 4)

HEAD OF RARE DISEASE Mutz Christopher sold $375,050 worth of shares (6,500 units at $57.70), decreasing direct ownership by 8% to 76,777 units (SEC Form 4)

SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $15,340 worth of shares (250 units at $61.36), decreasing direct ownership by 0.44% to 56,238 units (SEC Form 4)

$ANIP Leadership Updates

Live Leadership Updates

ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors

ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer

ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary

$ANIP SEC Filings

ANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ANIP Press Releases

Fastest customizable press release news feed in the world

ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance

ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November

ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET

$ANIP FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for HYDROCODONE BITARTRATE AND IBUPROFEN

FDA Approval for OXYCODONE AND ASPIRIN

FDA Approval for EZETIMIBE AND SIMVASTATIN

$ANIP Market Insights

Live Market Insights

ANI's Generic L-Glutamine Oral Powder Hits Market, Targets $20.1M Annual Sales

ANI Pharmaceuticals Announces FDA Approval And Launch Of Its Naproxen Delayed-Release Tablets, USP

NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday

$ANIP Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Piper Sandler initiated coverage on ANI Pharma with a new price target

CapitalOne initiated coverage on ANI Pharma with a new price target

H.C. Wainwright reiterated coverage on ANI Pharma with a new price target

$ANIP Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by ANI Pharmaceuticals Inc.

SEC Form SC 13D/A filed by ANI Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G filed by ANI Pharmaceuticals Inc.

$ANIP Financials

Live finance-specific insights

ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance

ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET

ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance

Recent Analyst Ratings for
$ANIP

$ANIP
Insider Trading

$ANIP
Leadership Updates

$ANIP
SEC Filings

$ANIP
Press Releases

$ANIP
FDA approvals

$ANIP
Market Insights

$ANIP
Analyst Ratings

$ANIP
Large Ownership Changes

$ANIP
Financials